Drug-Induced Cardiac Toxicity: Emphasizing the Role of Electrocardiography in Clinical Research and Drug Development

Journal of Electrocardiology

Volumn 37, Issue 1, 2004, Pages 19-24

  Gussak, Ihor ^a,b,d   Litwin, Jeffrey ^a   Kleiman, Robert ^a   Grisanti, Scott ^a   Morganroth, Joel ^a,c  

^a EResearch Technology Inc   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d eResearchTechnology Inc   (United States)

Author keywords

Cardiac toxicity; Clinical research; Drug development; ECG; QTc

Indexed keywords

ION CHANNEL; METOPROLOL; NEW DRUG; PROPAFENONE;

BRADYCARDIA; CARDIOTOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; ELECTROCARDIOGRAPHY; FIRST PASS EFFECT; HEART RATE VARIABILITY; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; REVIEW; SIGNAL PROCESSING;

EID: 0842327888     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2003.11.003     Document Type: Review

References (21)

1. Abernethy DR, Flockhart DA: Molecular basis of cardiovascular drug metabolism implications for predicting clinically important drug interactions. Circulation 101:1749, 2000
2. Roden DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 50:224, 2001
3. Ingelman-Sundberg M: Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342, 1999
4. Siddoway LA, Thompson KA, McAllister BC, et al: Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences. Circulation 75:785, 1987
5. Escande D: Pharmacogenetics of cardiac K + channels. Eur J Pharmacol 410:281, 2000
6. Legebrve RA, Van Peer A, Woestenborghs R: Influence of itraconazole on the pharmacokinetics and electrocardiographic effect of astemizole. Br J Clin Pharmacol 43:319, 1997
7. Neuvonen PJ, Kantola T, Kivisto KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332, 1998
8. Jahangir A, Terzic A, Shen W-K: Antiarrhythmic drugs, repolarization, and future direction, in Gussak I, Antzelevitch C, Hammil SC, et al (eds): Cardiac Repolarization: Bridging Basic and Clinical Science. Humana, Totowa, NJ, 2003
9. Nattel S: Effects of ionic remodeling on cardiac antiarrhythmic drug actions. J Cardiovasc Pharmacol 38:809, 2001
10. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 415:219, 2002
11. Roden DM, Spooner PM: Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 10:1664, 1999
12. Nattel S, Li DS: Ionic remodeling in the heart - Pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res 87:440, 2000
13. Abbott GW, Sesti F, Splawski I, et al: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175, 1999
14. Marban E: Cardiac channelopathies. Nature 10:213, 2002
15. Roden DM, Spooner PM: Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis. J Cardiovasc Electrophysiol 10:1664, 1999
16. Roden DM: Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 50:224, 2001
17. Abbott GW, Sesti F, Splawski I, et al: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175, 1999
18. Shah RR: Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 16:119, 2002
19. Yang P, Kanki H, Drolet B, et al: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105:1943, 2002
20. Morganroth J, Brown AM, Critz S, et al: Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 72:26B, 1993
21. Morganroth J: Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J Suppl 3: K105(suppl K), 2001